|
1
|
Breitenbuecher F, Schnittger S, Grundler
R, Markova B, Carius B, Brecht A, Duyster J, Haferlach T, Huber C
and Fischer T: Identification of a novel type of ITD mutations
located in nonjuxtamembrane domains of the FLT3 tyrosine kinase
receptor. Blood. 113:4074–4077. 2009. View Article : Google Scholar
|
|
2
|
O’Donnell MR, Appelbaum FR, Coutre SE,
Damon LE, Erba HP, Foran J, et al: Acute myeloid leukemia. J Natl
Compr Canc Netw. 6:962–993. 2008.
|
|
3
|
Foran JM: New prognostic markers in acute
myeloid leukemia: perspective from the clinic. Hematology Am Soc
Hematol Educ Program. 2010:47–55. 2010. View Article : Google Scholar
|
|
4
|
Scholl C, Gilliland DG and Frohling S:
Deregulation of signaling pathways in acute myeloid leukemia. Semin
Oncol. 35:336–345. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuchenbauer F, Kern W, Schoch C, Kohlmann
A, Hiddemann W, Haferlach T, et al: Detailed analysis of FLT3
expression levels in acute myeloid leukemia. Haematologica.
90:1617–1625. 2005.PubMed/NCBI
|
|
6
|
Kang HJ, Lee JW, Kho SH, Kim MJ, Seo YJ,
Kim H, et al: High transcript level of FLT3 associated with high
risk of relapse in pediatric acute myeloid leukemia. J Korean Med
Sci. 25:841–845. 2005. View Article : Google Scholar
|
|
7
|
Burnett AK: Acute myeloid leukemia:
treatment of adults under 60 years. Rev Clin Exp Hematol. 6:26–45.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Löwenberg B, Downing JR and Burnett A:
Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chu SH and Small D: Mechanisms of
resistance to FLT3 inhibitors. Drug Resist Updat. 12:8–16. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ravandi F, Kantarjian H, Faderl S,
Garcia-Manero G, O’Brien S, Koller C, Pierce S, Brandt M, Kennedy
D, Cortes J and Beran M: Outcome of patients with FLT3-mutated
acute myeloid leukemia in first relapse. Leuk Res. 34:752–756.
2010. View Article : Google Scholar
|
|
11
|
Levis M, Ravandi F, Wang ES, Baer MR, Perl
A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, et al:
Results from a randomized trial of salvage chemotherapy followed by
lestaurtinib for patients with FLT3 mutant AML in first relapse.
Blood. 117:3294–3301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kindler T, Lipka DB and Fischer T: FLT3 as
a therapeutic target in AML: still challenging after all these
years. Blood. 116:5089–5102. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Monnerat C, Henriksson R, Le Chevalier T,
Novello S, Berthaud P, Faivre S, et al: Phase I study of PKC412
(N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor,
combined with gemcitabine and cisplatin in patients with
non-small-cell lung cancer. Ann Oncol. 15:316–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Propper DJ, McDonald AC, Man A, Thavasu P,
Balkwill F, Braybrooke JP, et al: Phase I and pharmacokinetic study
of PKC412, an inhibitor of protein kinase C. J Clin Oncol.
19:1485–1492. 2001.PubMed/NCBI
|
|
15
|
Weisberg E, Boulton C, Kelly LM, Manley P,
Fabbro D, Meyer T, Gilliland DG and Griffin JD: Inhibition of
mutant FLT3 receptors in leukemia cells by the small molecule
tyrosine kinase inhibitor PKC412. Cancer Cell. 1:433–443. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Stone RM, DeAngelo DJ, Klimek V, Galinsky
I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, et al:
Patients with acute myeloid leukemia and an activating mutation in
FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor,
PKC412. Blood. 105:54–60. 2005. View Article : Google Scholar
|
|
17
|
Fischer T, Stone RM, Deangelo DJ, Galinsky
I, Estey E, Lanza C, et al: Phase IIB trial of oral Midostaurin
(PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and
multi-targeted kinase inhibitor, in patients with acute myeloid
leukemia and high-risk myelodysplastic syndrome with either
wild-type or mutated FLT3. J Clin Oncol. 28:4339–4345. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lotan R: Suppression of squamous cell
carcinoma growth and differentiation by retinoids. Cancer Res.
54(Suppl 7): 1987s–1990s. 1994.PubMed/NCBI
|
|
19
|
Caliaro MJ, Marmouget C, Guichard S,
Mazars P, Valette A, Moisand A, Bugat R and Jozan S: Response of
four human ovarian carcinoma cell lines to all-trans retinoic acid:
relationship with induction of differentiation and retinoic acid
receptor expression. Int J Cancer. 56:743–748. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amos B and Lotan R: Retinoid-sensitive
cells and cell lines. Methods Enzymol. 190:217–225. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Frankel SR, Eardley A, Lauwers G, Weiss M
and Warrell RP Jr: The “retinoic acid syndrome” in acute
promyelocytic leukemia. Ann Intern Med. 117:292–296. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Muindi J, Frankel SR, Miller WH Jr,
Jakubowski A, Scheinberg DA, Young CW, et al: Continuous treatment
with all-trans retinoic acid causes a progressive reduction in
plasma drug concentrations: implications for relapse and retinoid
“resistance” in patients with acute promyelocytic leukemia. Blood.
79:299–303. 1992.PubMed/NCBI
|
|
23
|
Conley BA, Egorin MJ, Sridhara R, Finley
R, Hemady R, Wu S, et al: Phase I clinical trial of
all-trans-retinoic acid with correlation of its pharmacokinetics
and pharmacodynamics. Cancer Chemother Pharmacol. 39:291–299. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Karmakar S, Banik NL and Ray SK:
Combination of all-trans retinoic acid and paclitaxel-induced
differentiation and apoptosis in human glioblastoma U87MG
xenografts in nude mice. Cancer. 112:596–607. 2008. View Article : Google Scholar
|
|
25
|
Ortiz MA, Bayon Y, Lopez-Hernandez FJ and
Piedrafita FJ: Retinoids in combination therapies for the treatment
of cancer: mechanisms and perspectives. Drug Resist Updat.
5:162–175. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arrieta O, González-De la Rosa CH,
Aréchaga-Ocampo E, Villanueva-Rodríguez G, Cerón-Lizárraga TL,
Martínez-Barrera L, Vázquez-Manríquez ME, et al: Randomized phase
II trial of All-trans-retinoic acid with chemotherapy based on
paclitaxel and cisplatin as first-line treatment in patients with
advanced non-small-cell lung cancer. J Clin Oncol. 28:3463–3471.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boorjian SA, Milowsky MI, Kaplan J, Albert
M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ
and Nanus DM: Phase 1/2 clinical trial of interferon alpha2b and
weekly liposome-encapsulated all-trans retinoic acid in patients
with advanced renal cell carcinoma. J Immunother. 30:655–662. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bryan M, Pulte ED, Toomey KC, Pliner L,
Pavlick AC, Saunders T and Wieder R: A pilot phase II trial of
all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in
patients with recurrent or metastatic breast cancer. Invest New
Drugs. 29:1482–1487. 2011. View Article : Google Scholar
|
|
29
|
Kini AR, Peterson LA, Tallman MS and
Lingen MW: Angiogenesis in acute promyelocytic leukemia: induction
by vascular endothelial growth factor and inhibition by all-trans
retinoic acid. Blood. 97:3919–3924. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ly BT, Chi HT, Yamagishi M, et al:
Inhibition of FLT3 expression by green tea catechins in FLT3
mutated-AML cells. PLoS One. 8:e663782013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Matsuo Y, MacLeod RA, Uphoff CC, Drexler
HG, Nishizaki C, Katayama Y, Kimura G, Fujii N, Omoto E, Harada M
and Orita K: Two acute monocytic leukemia (AML-M5a) cell lines
(MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity
showing MLL-AF9 fusion resulting from an occult chromosome
insertion, ins (11;9) (q23;p22p23). Leukemia. 11:1469–1477. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lange B, Valtieri M, Santoli D, Caracciolo
D, Mavilio F, Gemperlein I, et al: Growth factor requirements of
childhood acute leukemia: establishment of GM-CSF-dependent cell
lines. Blood. 70:192–199. 1987.PubMed/NCBI
|
|
33
|
Iida S, Saito M, Okazaki T, Seto M,
Yamamoto K, Akao Y, et al: Phenotypic and genotypic
characterization of 14 leukemia and lymphoma cell lines with 11q23
translocations. Leuk Res. 16:1155–1163. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Taketani T, Taki T, Sugita K, Furuichi Y,
Ishii E, Hanada R, Tsuchida M, Ida K and Hayashi Y: FLT3 mutations
in the activation loop of tyrosine kinase domain are frequently
found in infant ALL with MLL rearrangements and pediatric ALL with
hyperdiploidy. Blood. 103:1085–1088. 2004. View Article : Google Scholar
|
|
35
|
Furukawa Y, Vu HA, Akutsu M, Odgerel T,
Izumi T, Tsunoda S, et al: Divergent cytotoxic effects of PKC412 in
combination with conventional antileukemic agents in FLT3
mutation-positive versus -negative leukemia cell lines. Leukemia.
21:1005–1014. 2007.PubMed/NCBI
|
|
36
|
Steel GG and Peckham MJ: Exploitable
mechanisms in combined radiotherapy-chemotherapy: the concept of
additivity. Int J Radiat Oncol Biol Phys. 5:85–91. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kano Y, Akutsu M, Tsunoda S, Mori K,
Suzuki K and Adachi KI: In vitro schedule-dependent interaction
between paclitaxel and SN-38 (the active metabolite of irinotecan)
in human carcinoma cell lines. Cancer Chemother Pharmacol.
42:91–98. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Breitman TR, Collins SJ and Keene BR:
Terminal differentiation of human promyelocytic leukemic cells in
primary culture in response to retinoic acid. Blood. 57:1000–10004.
1981.PubMed/NCBI
|
|
39
|
Warrell RP Jr, Frankel SR, Miller WH Jr,
Scheinberg DA, Itri LM, Hittelman WN, Vyas R, And-reeff M, Tafuri
A, Jakubowski A, et al: Differentiation therapy of acute
promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N
Engl J Med. 324:1385–1393. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lotan R: Retinoids as modulators of tumor
cells invasion and metastasis. Semin Cancer Biol. 2:197–208.
1991.PubMed/NCBI
|
|
41
|
Hofmann SL: Retinoids--”differentiation
agents” for cancer treatment and prevention. Am J Med Sci.
304:202–213. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ashkenazi A, Holland P and Eckhardt SG:
Ligand-based targeting of apoptosis in cancer: the potential of
recombinant human apoptosis ligand 2/Tumor necrosis factor-related
apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol.
26:3621–3630. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Warrell RP Jr, de Thé H, Wang ZY and Degos
L: Acute promyelocytic leukemia. N Engl J Med. 329:177–189. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Degos L, Dombret H, Chomienne C, Daniel
MT, Micléa JM, Chastang C, Castaigne S and Fenaux P:
All-trans-retinoic acid as a differentiating agent in the treatment
of acute promyelocytic leukemia. Blood. 85:2643–2653.
1995.PubMed/NCBI
|
|
45
|
Das A, Banik NL and Ray SK: Retinoids
induced astrocytic differentiation with down regulation of
telomerase activity and enhanced sensitivity to taxol for apoptosis
in human glioblastoma T98G and U87MG cells. J Neurooncol. 87:9–22.
2008. View Article : Google Scholar
|
|
46
|
Nagai S, Takenaka K, Sonobe M, Wada H and
Tanaka F: Schedule-dependent synergistic effect of pemetrexed
combined with gemcitabine against malignant pleural mesothelioma
and non-small cell lung cancer cell lines. Chemotherapy.
54:166–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ridwelski K, Gebauer T, Fahlke J, Kröning
H, Kettner E, Meyer F, et al: Combination chemotherapy with
docetaxel and cisplatin for locally advanced and metastatic gastric
cancer. Ann Oncol. 12:47–51. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sarkar K and Yang H: Encapsulation and
extended release of anti-cancer anastrozole by stealth
nanoparticles. Drug Deliv. 15:343–346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sofou S: Radionuclide carriers for
targeting of cancer. Int J Nanomedicine. 3:181–199. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Torchilin V: Antibody-modified liposomes
for cancer chemotherapy. Expert Opin Drug Deliv. 5:1003–1025. 2008.
View Article : Google Scholar : PubMed/NCBI
|
